ARE YOUR ANTIBODIES WORKING HARD, OR HARDLY WORKING?

75% OF MANUFACTURED ANTIBODIES ARE NON-SPECIFIC OR DID NOT WORK AT ALL*

EVERY ANTIBODY THAT BETHYL SELLS IS MANUFACTURED TO EXACTING STANDARDS ON SITE IN MONTGOMERY, TX

TARGETING OVER **3,300** PROTEINS AND 1,500 SECONDARY ANTIBODIES



$350 MILLION IS WASTED ANNUALLY ON BIOMEDICAL RESEARCH BECAUSE POOR QUALITY MATERIALS LEAD TO FALSE RESULTS**

QUALIFIED ANTIBODIES
MADE IN THE USA
VALIDATED IN THE USA

40+ YEARS OF EXPERIENCE OF CATALOG & CUSTOM ANTIBODY PRODUCTION SERVICES

Bethyl is dedicated to improving lives by supporting scientific discovery through its qualified polyclonal and recombinant rabbit monoclonal antibody products and ELISA kits. Our antibodies have been manufactured and validated on-site by our scientists to ensure target specificity and sensitivity. If a product doesn't meet our standards, it doesn't leave our facility and every antibody sold is backed with a 100% guarantee to provide confidence in your results. We put a lot in every drop.

BETHYL LABORATORIES, INC | FORTIS LIFE SCIENCES

Really Good Antibodies

FIND OUT MORE AT BETHYL.COM/VALIDATION

BETHYL LABORATORIES

Since 1972, Bethyl Laboratories has been dedicated to improving lives by supporting scientific discovery through its qualified polyclonal and recombinant rabbit monoclonal antibody products and ELISA kits. Every antibody Bethyl sells has been manufactured and validated on site in the USA to exacting standards. Our in-house validation process ensures target specificity and sensitivity to provide confidence in your results. With over 40 years of experience, Bethyl is also a leading provider of bulk and custom production services. Bethyl's newest catalog offering of recombinant rabbit monoclonal antibodies serve to advance immuno-oncology research. To learn more, please visit www.bethyl.com. We put a lot in every drop.



BETHYL LABORATORIES, INC | FORTIS LIFE SCIENCES

STARS OF THE SHOW

THE IMMUNE SYSTEM PLAYS A PIVOTAL ROLE IN TUMOR FORMATION, DEVELOPMENT, AND METASTASIS.

Sponsored by: BETHYL LABORATORIES, INC | FORTIS LIFE SCIENCES

Light your way.

Get the full picture with trusted tumor immune response results from our in-house validated antibodies.

When it comes to your tumor immune response research, blind spots are unacceptable. Independent testing has demonstrated that 75% of antibodies in today's market are non-specific or simply do not work at all.* But at Bethyl, we've manufactured and validated every antibody we make on site to ensure target specificity and sensitivity. All to guarantee our antibodies will function as designed in your assay 100% of the time. More than 10,000 independent citations over the past 15 years have proven that, at Bethyl, we put a lot in every drop.

See our data at bethyl.com/immuno-oncology

*Weller, MG, Analytical Chemistry Insights: 11, 21-27 (2016).

Antibodies shown: Rabbit anti-PD-L1 (red, A700-020) & Lamin-A/C (green, A303-430A) in FFPE lung.

BETHYL LABORATORIES, INC | FORTIS LIFE SCIENCES

STARS OF THE SHOW

The immune system plays a pivotal role in tumor formation, development, and metastasis. Cancer cells are inherently antigenic,[1] which normally allows immune cells to identify and eliminate them prior to tumor formation. Tumor formation occurs when cancer cells develop methods to evade or outpace immune-mediated killing. Understanding this relationship between immune and cancer cells is therefore integral to restoring immune system potency for cancer therapeutics.

T CELLS

The primary effectors of immune-mediated cell death, T cells exert their tumoricidal functions by recognizing antigens presented on tumor cells' surfaces.[2] Tumor cells evade T cells through nutrient deprivation,[3] promoting cell inactivation, and activating immunosuppression mechanisms.[4] Augmenting T cell activity to counteract these effects is a primary focal point of immuno-oncology research.



General T cell surface marker CD3 expression (orange) in FFPE human tonsil.

NATURAL KILLER (NK) CELLS

Mechanism:

- Effectively eliminates circulating cancer cells via cytotoxic mechanisms[11]
- Activity against solid tumors is dependent on extent of cytokine-mediated activation[11]

Markers:
CD95, CD117, CD62L, $CD56_{dim}$ or $CD56_{bright}12$



CD117 (red) in FFPE human small-cell lung carcinoma.

CYTOTOXIC T CELLS (CTLs)

Mechanism:

- Primed and activated through T cell receptor (TCR)–major histocompatibility complex (MHC)–antigen presentation
- Releases cytotoxins to kill cells expressing said antigen

Markers:
CD8, $CD44_v$, $CD62_L$[4]



CD44 (green) in FFPE human colon carcinoma.

HELPER T CELLS (T_H CELLS)

Mechanism:

- Regulates immune system function through cytokine secretion and activation of macrophages, B cells, and CTLs
- Vital for anti-tumor protection[3]

Markers: CD4; distinguished from T_{reg} cells (also CD4+) by secretion profile (T_H1 cells secrete IFNγ, T_H2 interleukins (ILs) 4, 13, and 5, and T_H17 ILs 17 and 21)[4]



CD4 (orange) in FFPE human tonsil.

REGULATORY T CELLS (T_{REG} CELLS)

Mechanism:

- Suppresses immune system activity to prevent deleterious inflammation and autoimmune disorders[7]
- Tumor cells promote T_{reg} recruitment, resulting in immunosuppression and evasion[8]

Markers:
FoxP3, CD25R



FoxP3 (magenta) in FFPE human tonsil.

DENDRITIC CELLS AND MACROPHAGES: ANTIGEN PRESENTING CELLS (APCs)

Mechanism:

- Dendritic cells (DCs) and macrophages are professional antigen-presenting cells (APCs) pivotal for activating T cells[13]
- Macrophages also kill cells via phagocytosis or cytotoxic mechanisms; phenotypes range from pro-inflammatory to anti-inflammatory/pro-repair[14]
- Cancer cell-secreted cytokines cause tumor-infiltrating DCs to switch to an immuno-suppressive phenotype, while tumor-associated macrophages (TAMs) present anti-inflammatory phenotypes, inhibit T cell activity, and promote angiogenesis, tumor growth, and metastasis[13,14]

DC Markers: CD1c, CD14, CD141[15]
Macrophage Markers: CD14, CD11b, CD68, HLA-DR, CD163, CX3CR1[16]



Macrophage-marker CD68 expression (magenta) in FFPE human tonsil.

IMMUNE CHECKPOINTS

Mechanism:

- Checkpoint proteins and the pathways they activate are critical for immune self-regulation[19]
- The ability to inhibit immune responses is key for limiting collateral damage and maintaining self-tolerance[19]
- Cancer cells have co-opted the activation of these pathways to deactivate immune-mediated tumoricidal mechanisms, thereby facilitating tumor immune evasion[19]
- Checkpoint inhibition – using exogenous agents to prevent cancer cell–mediated checkpoint pathway activation – is a popular anti-cancer therapeutic strategy undergoing intensive research[19]

Checkpoint Pathway Proteins: PD-1, PD-L1; CTLA-4, CD80/CD86[19,20]



PD-L1 (orange) in FFPE human lung carcinoma.

ENDOTHELIAL CELLS

Mechanism:

- Regulates and promotes angiogenesis[23]
- Controls tumor cell intra/extravasation, metastasis, and immune cell infiltration[23]

Markers: CD31, von Willebrand Factor[24]



CD31 expression (red) in FFPE human breast carcinoma.

B CELLS

Mechanism:

- Produces antibodies that promote anti-tumor T cell, macrophage, and NK cell activity[9]
- Can encourage tumor development by producing growth factors and autoantibodies[9]

Markers:
CD19, CD20, CD21, CD40, CD80, CD86, & CD69[10]



CD20 (yellow) in FFPE human tonsil.

CANCER CELL MARKERS

Mechanism:

- Cancer stem cells are resistant to anti-tumor therapies and are capable of self-renewal, facilitating disease relapse and metastasis[17]
- Host mesenchymal stem cells can differentiate into immunosuppressive immune cells[18]

Markers: β-catenin, PCNA, Ki-67, cytokeratin



PCNA expression (magenta) in FFPE human head and neck squamous cell carcinoma.

FIBROBLASTS

Mechanism:

- Creates a favorable environment for tumor growth by secreting growth factors and extracellular matrix[21]
- Promotes angiogenesis as well as recruitment of vascular cells (e.g., endothelial cells and pericytes)[21]

Markers: α-smooth muscle actin, vimentin, desmin, platelet derived growth factor receptor[22]



Vimentin expression (red) in FFPE human breast carcinoma.

1. T.F. Gajewski, et al., "Innate and adaptive immune cells in the tumor microenvironment," *Nat Immunol* 14(10):1014–1022, 2013.
2. M. Sharpe and N. Mount, "Genetically modified T cells in cancer therapy: opportunities and challenges," *Dis Model Mech* 8(4):337–350, 2015.
3. B. Motzer, et al., "T Cells and Cancer: How Metabolism Shapes Immunity," *Front Immunol* 7:20, 2016.
4. Y. Jiang, et al., "T-cell exhaustion in the tumor microenvironment," *Cell Death Dis* 6:e1792, 2015.
5. M. Zanetti, "Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics," *J Immunol* 194(5):2049–2056, 2015.
6. K. J. Kim and K. Cantor, "CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful," *Cancer Immunol Res* 2(2):91–98, 2014.
7. G.Z. Josefowicz, et al., "Regulatory T cells: mechanisms of differentiation and function," *Annu Rev Immunol* 30:531–564, 2012.
8. A. Chaudhary and E. Elkord, "Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting," *Vaccines (Basel)* 4(3), 2016.
9. G.J. Yuen, et al., "B lymphocytes and cancer: a love-hate relationship," *Trends Cancer* 2(12):747–757, 2016.
10. D.A. Kaminski, et al., "Advances in Human B Cell Phenotypic Profiling," *Front Immunol* 3:302, 2012.
11. S.K. Larsen, et al., "NK Cells in the Tumor Microenvironment," *Crit Rev Oncog* 19(1):91–105, 2014.
12. E. Montaldo, et al., "Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function," *Cytometry A* 83(8):702–713, 2013.
13. J.M. Tran Janco, et al., "Tumor-Infiltrating dendritic cells in cancer pathogenesis," *J Immunol* 194(7):2985–2991, 2015.
14. Y. Lin and X. Lao, "The origin and function of tumor-associated macrophages," *Cell Mol Immunol* 12(1):1–4, 2015.
15. M. Collin, et al., "Human dendritic cell subsets," *Immunology* 140(1): 22–30, 2013.
16. L. Cassetta, et al., "Isolation of Mouse and Human Tumor-Associated Macrophages," *Adv Exp Med Biol* 899:211–229, 2016.
17. A. Albini, et al., "Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity," *Connect Tissue Res* 56(5):414–425, 2015.
18. J. Guan and J. Chen, "Mesenchymal stem cells in the tumor microenvironment," *Biomed Rep* 1(4):517–521, 2013.
19. M. Postow, "The blockade of immune checkpoints in cancer immunotherapy," *Nat Rev Cancer* 12(4):252–264, 2012.
20. J. Weber, "Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade," *Semin Oncol* 37(5):430–439, 2010.
21. R. Kalluri and M. Zeisberg, "Fibroblasts in cancer," *Nat Rev Cancer* 6(5):392–401, 2006.
22. K. Shiga, et al., "Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth," *Cancers (Basel)* 7(4):2443–2458, 2015.
23. S. Chouaib, et al., "Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells," *Crit Rev Immunol* 30(6):529–545, 2010.
24. J. Middleton, et al., "A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146," *J Pathol* 206(3):260–268, 2005.